There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Wenjie Cai |
| Institution: | Harvard University T.H.Chan School of Public Health |
| Department: | Epidemiology |
| Country: | |
| Proposed Analysis: | Title: The association between neuropsychiatric symptoms and cognitive decline in asymptomatic Alzheimer’s disease patients Background: Neuropsychiatric symptoms in Alzheimer’s disease (AD) include depression, apathy, agitation, aggression, and psychosis1. There was some evidence of the association between neuropsychiatric symptoms and cognition decline in Alzheimer’s disease2, 3. However, the trajectories of the neuropsychiatric symptoms and cognition decline in AD patients don’t match1, 4. The relationship between neuropsychiatric symptoms in AD and cognition remains unclear and needed to be focused on so that a better understanding could enhance precision in disease models and for better therapeutic options1. Thus, it is important to explore the association between neuropsychiatric symptoms and cognition, AD biomarkers, and clinical progression in asymptomatic AD patients within longitudinal studies. Study Objective: To explore whether neuropsychiatric symptoms are associated with cognition and cognitive decline in asymptomatic AD patients (patients with Alzheimer’s pathologic change) Hypothesis: More severe neuropsychiatric symptoms are associated with worse cognition and cognitive decline in asymptomatic AD patients. Study design and approach: A longitudinal study using the data collected from the ADNI study which recruited the asymptomatic AD patients. The exposure is the neuropsychiatric symptoms measured at the baseline. The outcome is cognition and cognitive decline. Statistical analysis: 1) The association between neuropsychiatric symptoms and cognition at the baseline will be explored by using a linear regression model, adjusting for sex, age, education level, APOE e4 status, and psychotropic medication usage. 2) The association between baseline neuropsychiatric symptoms and cognitive decline will be explored by using a linear mixed effects model, adjusting for sex, age, education level, APOE e4 status, and psychotropic medication usage. References: 1. Sanders AE. Cognition and Neuropsychiatric Symptoms in Alzheimer Disease: A Century-Old Problem. Neurology 2021;97:615-616. 2. Zahodne LB, Ornstein K, Cosentino S, Devanand DP, Stern Y. Longitudinal relationships between Alzheimer disease progression and psychosis, depressed mood, and agitation/aggression. Am J Geriatr Psychiatry 2015;23:130-140. 3. Stella F, Laks J, Govone JS, de Medeiros K, Forlenza OV. Association of neuropsychiatric syndromes with global clinical deterioration in Alzheimer's disease patients. Int Psychogeriatr 2016;28:779-786. 4. Eikelboom WS, van den Berg E, Singleton EH, Baart SJ, Coesmans M, Leeuwis AE, et al. Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations. Neurology 2021;97:e1276-e1287. |
| Additional Investigators |
